Summary
This randomized, double-blind, double-dummy parallel study compared the anti-emetic efficacy and tolerability of the serotonin antagonist granisetron with prednisolone plus the dopamine D2 antagonist metopimazine during nine cycles of moderately emetogenic chemotherapy. Chemotherapy naive women with stage I or II breast cancer scheduled to intravenous cyclophosphamide, fluorouracil and methotrexate or cyclophosphamide, epirubicin and fluorouracil every 3 weeks were included. Patients received a single intravenous dose of granisetron 3 mg or a 3-day oral treatment with prednisolone 25 mg once a day plus metopimazine 30 mg four times a day. A total of 223 women were enrolled and 218 patients (97.8%) were evaluable for efficacy. Granisetron (n = 109) was superior to prednisolone plus metopimazine (n = 109) in the prophylaxis of acute nausea and vomiting during the first cycle of chemotherapy (P < 0.001) and prednisolone plus metopimazine was superior on days 2–5 (P = 0.002). Overall, granisetron was superior on days 1–5 (P = 0.009). The median number of cycles completed with granisetron was five (95% confidence interval 4–6) compared with two (95% confidence interval 2–2) for prednisolone plus metopimazine (P = 0.0019). Constipation and rash were reported more frequently with granisetron (P < 0.001 and P = 0.043 respectively) and palpitations more frequently with prednisolone plus metopimazine (P = 0.015). In conclusion, the number of cycles completed with granisetron was significantly higher than the number completed with prednisolone plus metopimazine, but the anti-emetic efficacy of both treatments declined during multiple cycles of moderately emetogenic chemotherapy.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aapro, M. S. (1991). Controling emesis related to cancer therapy. Eur J Cancer 27: 356–361.
Adams, V. R. & Valley, A. W. (1995). Granisetron: the second serotonin-receptor antagonist. Ann Pharmacother 29: 1240–1251.
Andrews, P. L. R. & Davis, C. J. (1993). The mechanism of emesis induced by anticancer therapies. In Emesis in Anticancer Therapy, 1st Edn, Andrews PLA and Sanger GJ (eds), pp. 113–161. Chapman & Hall: London
Blijham, H. G. (1992). Does granisetron remain effective over multiple cycles? Eur J Cancer 28A: S17–S21.
Bonneterre, J., Chevallier, B., Metz, R., Fargeot, P., Pujade-Laurine, E., Spielmann, M., Tubiana-Hulin, M., Paes, D. & Bons, J. (1990). A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol 8: 1063–1069.
Campora, E., Simoni, C. & Rosso, R. (1994). Tropisetron verso ondansetron nella preventione e controllo dellémesi in pazienti sottoposte a chemioterapia con FAC/FEC per carcinoma mammario metastatico o operato. Minerva Med 85: 25–31.
Cersosimo, R. J. & Karp, D. D. (1986). Adrenal corticosteroids as antiemetics during cancer chemotherapy. Pharmacotherapy 6: 118–127.
Chiara, S., Campora, E., Lionetto, R., Bruzzi, P. & Rosso, R. (1987). Methylprednisolone for the control of CMF-induced emesis. Am J Clin Oncol 10: 264–267.
Clavel, M., Soukop, M. & Greenstreet, Y. L. A. (1993). Improved control of emesis and quality of life with ondansetron in breast cancer. Oncology 50: 180–183.
Coleman, R. E., Twelves, C. J., O’Reilly, S. M., Rubens, R. D., Richards, M. A. & Harper, P. G. (1991). Influence of dexamethasone dose on the control of chemotherapy-induced nausea and vomiting. Eur J Cancer 27: 1062–1063.
de Wet, M., Falkson, G. & Rapoport, L. (1993). Repeated use of granisetron in patients receiving cytostatic agents. Cancer 71: 4043–4049.
De Wit, R., Schmitz, P. I. M., Verweij, J., De Boer-Dennart, M., De Mulder, P. H. M., Planting, A. S. T., Van Der Burg, M. E. L. & Stoter, G. (1996). Analysis of cumultative probabilities shows that the efficacy of 5-HT3 antagonist prophylaxis is not maintained. J Clin Oncol 14: 644–651.
Early Breast Cancer Trialists’ Collaborative Group (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 71–85.
Gebbia, V., Cannata, G., Testa, A., Curto, G., Valenza, R., Cipolla, C., Latteri, M. A. & Gebbia, N. (1994). Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer 74: 1945–1952.
Gez, E., Strauss, N., Vitzhaki, N., Cass, Y. & Edelmann, D. Z. (1992). Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules. Cancer Chemother Pharmacol 30: 229–232.
Havsteen, H. & Kjær, M. (1996). Antiemetic treatment with two different doses of methylprednisolone in breast cancer patients: a double-blind randomized cross-over study with evaluation of efficacy parameters. Anti-Cancer Drugs 7: 535–542.
Herrstedt, J., Sigsgaard, T., Boesgaard, M., Jensen, T. P. & Dombernowsky, P. (1993). Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 328: 1076–1080.
Herrstedt, J., Sigsgaard, T., Angelo, H. R., Kampmann, J. P. & Hansen, M. (1997). Dose-finding study of oral metopimazine. Support Care Cancer 5: 38–43.
Ibrahim, E. M., Al-Idrissi, H. Y., Ibrahim, A., Absood, G., Al-Dossary, E., Al-Jammaa, A., Al-Ethan, S. & Eliopoulos, A. (1986). Antiemetic efficacy of high-dose dexamethasone: Randomized, double-blind, crossover study with high-dose metoclopramide in patients receiving cancer chemotherapy. Eur J Cancer Clin Oncol 22: 283–288.
Israel, L. & Rodary, C. (1978). Treatment of nausea and vomiting related to anti-cancerous multiple combination chemotherapy: results of two controlled studies. J Int Med Res 6: 235–240.
Italian Group for Antiemetic Research (1994). Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Ann Oncol 5: 585–589.
Italian Group for Antiemetic Research (1995a). Persistence of efficacy of three antiemetic regimens and prognostic factors in patients undergoing moderately emetogenic chemotherapy. J Clin Oncol 13: 2417–2426.
Italian Group for Antiemetic Research (1995b). Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332: 1–5.
Jones, A., Hill, A. S., Soukop, M., Hutcheon, A. W., Cassidy, J., Kaye, S. B., Sikora, K., Carney, D. N. & Cunningham, D. (1991). Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338: 483–487.
Kaasa, S., Kvaløy, S., Dicato, M. A., Ries, F., Huys, J. V., Royer, E. & Carruthers, L. (1990). A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: A randomized, double-blind study. Eur J Cancer 26: 311–314.
Kaizer, L., Warr, D., Hoskins, P., Latreille, J., Lofters, W., Yau, J., Palmer, M., Zee, B., Levy, M. & Pater, J. (1994). Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12: 1050–1057.
Koo, W. H. & Ang, P. T. (1996). Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 7: 71–74.
Kris, M. G., Gralla, R. J., Tyson, L. B., Clark, R. A., Cirrincione, C. & Groshen, S. (1989). Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 7: 108–114.
Levitt, M., Warr, D., Yelle, L., Rayner, H. L., Lofters, W. S., Perrault, D. J., Wilson, K. S., Latreille, J., Potvin, M., Warner, E., Pritchard, K. I., Palmer, M., Zee, B. & Pater, J. L. (1993). Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med 328: 1081–1084.
Markman, M., Sheidler, V., Ettinger, D. S., Quaskey, S. A. & Mellits, E. D. (1984). Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med 311: 549–552.
Marschner, N. W., Adler, M., Nagel, G. A., Christmann, D., Fenzl, E. & Upadhyaya, B. (1991). Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubucin and cyclophosphamide. Eur J Cancer 27: 1137–1140.
Martin, M., Diaz-Rubio, E., Casado, A., Dominguez, S. & Sastra, J. (1992). Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy. Eur J Cancer 28: 430–432.
Marty, M. (1990). A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard enti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 26: S28–S32.
Matsui, K., Fukuoka, M., Takada, M., Kusunoki, Y., Yana, T., Tamura, K., Yoshida, T., Iida, K., Hirashima, T., Tsukada, H., Ushijima, S., Miyawaki, H. & Masuda, N. (1996). Randomized trial for the prevention of delayed emesis in patients receiving high-dose cisplatin. Br J Cancer 73: 217–221.
Moertel, C. G. & Reitemeier, R. J. (1973). Controlled studies of metopimazine for the treatment of nausea and vomiting. J Clin Pharmacol 13: 283–287.
Moreno, I., Rosell, R., Abad, A., Barnadas, A., Carles, J., Ribelles, N., Solano, V. & Font, A. (1992). Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer 28A: 1344–1347.
Münstedt, K., Milch, W., Blaunth-Eckmeyer, E., Spänle, A., Vahrson, H. & Reimer, C. (1995). Prevention of cisplatinum-induced delayed emesis and nausea. Onkologie 18: 23–26.
Perez, E. A., Hesketh, P., Sandbach, J., Reeves, J., Chawla, S., Markman, M., Hainsworth, J., Bushnell, W. & Friedman, C. (1998). Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 16: 754–760.
Pollera, C. F., Nardi, M., Marolla, P., Pinnaro, P., Terzoli, E. & Giannarelli, D. (1989). Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo. Am J Clin Oncol 12: 524–529.
Roila, F., Basurto, C., Minotti, V., Ballatori, E., Tonato, M. & Del Favero, A. (1988). Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study. Oncology 45: 346–349.
Roila, F., Boschetti, E., Tonato, M., Basurto, C., Bracarda, S., Picciafuoco, M., Patoia, L., Santi, E., Penza, O., Ballatori, E. & Del Favero, A. (1991). Predictive factors of delayed emesis in cisplatin-treated patients and antiemetic activity and tolerability of metoclopramide or dexamethasone. Am J Clin Oncol 14: 238–242.
Silva, R. R., Bascioni, R., Giorgi, F., Acito, L., De Signoribus, G., Marcellini, M., Menichetti, E. T. & Giuliodori, L. (1996). Granisetron plus dexamethasone in moderately emetogenic chemotherapy: evaluation of activity during three consecutive courses of chemotherapy. Support Care Cancer 4: 287–290.
Soukop, M., McQuade, B., Hunter, E., Stewart, A., Kaye, S., Cassidy, J., Kerr, D., Khanna, S., Smyth, J., Coleman, R., Cunningham, D., Powels, T., Davidson, N., Hutcheon, A., Green, J., Slater, A., Rustin, G. & Carney, D. (1992). Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 49: 295–304.
Stewart, A., McQuade, B., Cronje, J. D. E., Goedhals, L., Gudgeon, A., Corette, L., Froger, X., Tubiana-Hulin, M., Laplaige, P., Roberts, J. T., Mcrae, J., Forster, J., Parasuraman, T. V. & Butcher, M. (1995). Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: A multicenter, double-blind, double-dummy, randomised parallel-group study. Oncology 52: 202–210.
Tonato, M., Roila, F. & Del Favero, A. (1991). Methodology of antiemetic trials: A review. Ann Oncol 2: 107–114.
Vallejo, C., Rabinovich, M., Leone, B. & Gonzalez, J. (1988). Toxicity and dose-response of intravenous (i.v.) metopimazine (MPZ) as preventive of high-dose cisplatin (CDDP)-induced emesis. Proc Am Soc Clin Oncol 7: 286 (Abstract)
Warr, D., Willan, A., Fine, S., Wilson, K., Davis, A., Erlichman, C., Rusthoven, J., Lofters, W., Osoba, D., Laberge, F., Latreille, J. & Pater, J. (1991). Superiority of granisetron to dexamethasone plus pro0chlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst 83: 1169–1173.
World Health Organisation (1979). Handbook for Reporting Results of Cancer Treatment. World Health Organisation: Bask
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Sigsgaard, T., Herrstedt, J., Andersen, L. et al. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. Br J Cancer 80, 412–418 (1999). https://doi.org/10.1038/sj.bjc.6690372
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690372
Keywords
This article is cited by
-
Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis
Medical Oncology (2018)
-
Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy
Medical Oncology (2016)
-
Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin
Supportive Care in Cancer (2014)
-
Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy
Supportive Care in Cancer (2007)
-
Acute emesis: moderately emetogenic chemotherapy
Supportive Care in Cancer (2005)